BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feng Y, Wu H, Huang DQ, Xu C, Zheng H, Maeda M, Zhao X, Wang L, Xiao F, Lv H, Liu T, Qi J, Li J, Zhong N, Wang C, Feng H, Liang B, Ren W, Qin C, Nguyen MH, Zhu Q. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection.Eur Radiol. 2020;30:6357-6368. [PMID: 32529568 DOI: 10.1007/s00330-020-06990-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chua DW, Koh YX, Syn NL, Chuan TY, Yao TJ, Lee SY, Goh BKP, Cheow PC, Chung AY, Chan CY. Repeat hepatectomy versus radiofrequency ablation in management of recurrent hepatocellular carcinoma: an average treatment effect analysis. Ann Surg Oncol 2021. [PMID: 33969464 DOI: 10.1245/s10434-021-09948-2] [Reference Citation Analysis]
2 Ma H, Li Z, Yuan J, Zhang L, Xie X, Yin X, Chen R, Ren Z. Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation. Gastroenterol Res Pract 2021;2021:8878417. [PMID: 33488700 DOI: 10.1155/2021/8878417] [Reference Citation Analysis]
3 Yang Y, Yu H, Tan X, You Y, Liu F, Zhao T, Qi J, Li J, Feng Y, Zhu Q. Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2021;38:875-86. [PMID: 34078221 DOI: 10.1080/02656736.2021.1933218] [Reference Citation Analysis]
4 Zhong JH, Xing BC, Zhang WG, Chan AW, Chong CCN, Serenari M, Peng N, Huang T, Lu SD, Liang ZY, Huo RR, Wang YY, Cescon M, Liu TQ, Li L, Wu FX, Ma L, Ravaioli M, Neri J, Cucchetti A, Johnson PJ, Li LQ, Xiang BD. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a retrospective multicentre study. Br J Surg 2021:znab340. [PMID: 34643677 DOI: 10.1093/bjs/znab340] [Reference Citation Analysis]
5 Liu C, Yu H, Li X, Gong Y, Wu P, Feng QS. Anti-hepatocellular carcinoma efficacy of Fuzheng Xiaozheng prescription and its interventional mechanism studies. J Ethnopharmacol 2022;285:114913. [PMID: 34910953 DOI: 10.1016/j.jep.2021.114913] [Reference Citation Analysis]
6 Chen QF, Liu S, Lyu N, Jia Z, Chen M, Zhao M. Surveillance Strategy after Complete Ablation of Initial Recurrent Hepatocellular Carcinoma: A Risk-Based Machine Learning Study. J Vasc Interv Radiol 2021;32:1548-1557.e2. [PMID: 34474127 DOI: 10.1016/j.jvir.2021.07.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kim HS, Yi NJ, Kim JM, Joh JW, Lee KW, Suh KS. Clinical impact of the treatment modality on small, solitary, recurrent intrahepatic hepatocellular carcinomas after primary liver resection. Ann Surg Treat Res 2021;101:85-92. [PMID: 34386457 DOI: 10.4174/astr.2021.101.2.85] [Reference Citation Analysis]
8 Bo XW, Sun LP, Yu SY, Xu HX. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World J Gastrointest Oncol 2021; 13(10): 1397-1411 [PMID: 34721773 DOI: 10.4251/wjgo.v13.i10.1397] [Reference Citation Analysis]
9 Zhou Z, Zhou Z, Huang Z, He S, Chen S. Histone-fold centromere protein W (CENP-W) is associated with the biological behavior of hepatocellular carcinoma cells. Bioengineered 2020;11:729-42. [PMID: 32635817 DOI: 10.1080/21655979.2020.1787776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
10 Yamamoto T, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, Matsushita T, Ishigami M, Fujishiro M. Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma patients with haemophilia. Haemophilia 2021;27:100-7. [PMID: 33245832 DOI: 10.1111/hae.14220] [Reference Citation Analysis]